×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Module 4: Phase 2
Session Chair(s)
Courtland R. LaVallee, MBA
Executive Director, Project Management
Dynavax Technologies, United States
- Demonstration of Desired Pharmacologic Effect (Biomarkers) in Humans
- Preliminary Efficacy/Safety in Humans
- Potential Therapeutic Dose Range
- Chronic Animal Toxicology
- Reproductive Toxicology